During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, discussed the TRIDENT-1 trial and practical considerations for ...

Associate Health Minister with responsibility for Pharmac David Seymour, and Health Minister Simeon Brown welcome Pharmac’s ...

Associate Health Minister with responsibility for Pharmac David Seymour, and Health Minister Simeon Brown welcome Pharmac's decision to fund medicines for a further five health conditions, including ...

Learn how new research and clinical trials at Memorial Sloan Kettering Cancer Center (MSK) have helped 32-year-old Giancarlo ...

Genetic testing helps determine whether any specific gene mutations are driving your lung cancer. Once a mutation is identified, a doctor may modify your cancer treatment to target it. A genetic ...

Reply to: Treatment Intensification Based on Residual Disease in Elderly Patients With AML ...

1Division of Oncology and Center for Childhood Cancer Research, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania.

Targeting oncogenic ROS1 fusion proteins with crizotinib has shown promising clinical outcomes in non-small cell lung cancer (NSCLC) patients, but emergence of resistance to therapy has been reported.

The court found that Prakash and other defendants sold a drug akin to Sugen’s drug Crizotinib in an older version of their website. The court found the defendants guilty of infringing Sugen’s patent.

Esophageal cancer (EC) remains a significant challenge globally, having the 8th highest incidence and 6th highest mortality worldwide. Esophageal squamous cell carcinoma (ESCC) is the most common form ...

Herein, we reported that the use of crizotinib, a ROS1 inhibitor, exerted favorable survival benefit (exceeded 29 months) in a resectable stage IIIA NSCLC patient with novel LDLR–ROS1 fusion. A ...